Device Trial Radar · NCT04927702
Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
48
Actual
Start
Jul 19, 2021
Primary completion
Jul 15, 2024
Study completion Aug 1, 2024
Sponsor
- Lead sponsor
- Acera Surgical, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 16, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care. In participants with venous leg ulcers (VLUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with living cellular skin substitute (Apligraf®)
Conditions
- Diabetic Foot Ulcer
- Venous Leg Ulcer
Interventions
Synthetic Hybrid-Scale Fiber MatrixDevice
A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.
Standard of CareDevice
To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.
Living Cellular Skin SubstituteDevice
An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.
Primary outcomes
What the sponsor says the trial is designed to measure.
- For Diabetic Foot Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of WoundTime frame: 12 weeks
- For Venous Leg Ulcers, Number of Wounds With 100 Percent Epithelialization (Closure) of WoundTime frame: 16 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
ILD Research Center
Vista, California
University of Florida - Jacksonville
Jacksonville, Florida
Barry University
Miami Beach, Florida
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.